育龄期女性癌症患者生育力保存服务的使用情况
该研究利用MarketScan数据库纳入2009至2016年接受手术和化疗的18-45岁肺癌、乳腺癌、结直肠癌或宫颈癌女性18781例,分析生育力保存服务的利用率和预测因素。结果显示年轻女性中接受评估、实验室检测和保存操作的比例分别为11.7%、13.7%和6.3%,且从2009年到2016年评估率从1.0%升至5.5%,操作率从1.0%升至4.6%。作者结论认为尽管存在缺乏癌症分期和未来生育意愿信息的局限,全国样本中仅小部分接受化疗的育龄女性癌症患者接受了生育力保存评估或操作。
要点
- 18-35岁女性中11.7%接受生育力保存评估,13.7%接受实验室检测,6.3%接受保存操作。
- 36-40岁女性对应比例为3.3%、7.5%、1.9%,41-45岁为0.5%、7.2%、0.3%。
- 2009至2016年评估率从1.0%升至5.5%(风险比4.66,95%CI 2.38-9.11),操作率从1.0%升至4.6%(风险比3.84,95%CI 1.94-7.59)。
核心结论
- 尽管存在缺乏癌症分期和未来生育意愿信息的局限,全国样本中仅小部分接受化疗的育龄女性癌症患者接受了生育力保存评估或生育力保存操作。
研究设计与样本
- 使用MarketScan数据库识别2009年至2016年接受手术和化疗的18-45岁肺癌、乳腺癌、结直肠癌或宫颈癌女性。
- 共纳入18781例女性,包括宫颈癌386例、结直肠癌1372例、肺癌246例和乳腺癌16777例。
- 采集化疗前3个月至化疗后3个月内的生育力保存评估、生育力评估实验室检测和生育力保存操作服务。
- 采用多变量模型评估与生育力保存服务使用相关的因素。
主要发现
- 18-35岁女性中,11.7%接受生育力保存评估,13.7%接受实验室检测,6.3%接受生育力保存操作。
- 36-40岁女性中,办公室评估、实验室检测和操作的比例分别为3.3%、7.5%和1.9%;41-45岁女性分别为0.5%、7.2%和0.3%。
- 生育力保存评估率从2009年的1.0%升至2016年的5.5%(风险比4.66,95%置信区间2.38-9.11)。
- 生育力保存操作使用率从2009年的1.0%升至2016年的4.6%(风险比3.84,95%置信区间1.94-7.59)。
- 多变量模型中,任何生育力保存干预在乳腺癌患者(调整风险比2.30,95%置信区间1.30-4.06)、东北部地区患者(调整风险比1.24,95%置信区间1.10-1.40)和年轻女性(18-35岁)(调整风险比2.59,95%置信区间2.32-2.89)中更常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出局限包括缺乏癌症分期和未来生育意愿的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to determine the rates and predictors of fertility preservation services among reproductive-aged women with common cancers in the United States. STUDY DESIGN: We used the MarketScan database to identify women 18-45 years of age with lung, breast, colorectal, or cervical cancer who underwent surgery and chemotherapy from 2009 through 2016. Services from 3 months before to 3 months after chemotherapy for evaluation for fertility preservation, laboratory testing for fertility evaluation, and fertility-preserving procedures were captured. Multivariable models were used to assess the factors associated with the use of fertility-preservation services. RESULTS: A total of 18,781 women, including 386 cervical, 1372 colorectal, 246 lung, and 16,777 with breast cancer, were identified. In women 18-35 years old, 11.7% underwent evaluation for fertility preservation, 13.7% underwent laboratory testing, and 6.3% pursued fertility-preserving procedures. The rates of office evaluation, laboratory testing, and performance of procedure were 3.3%, 7.5%, and 1.9 % in women aged 36-40 years and 0.5%, 7.2%, and 0.3% in those aged 41-45 years, respectively. The rate of fertility preservation evaluation rose from 1.0% in 2009 to 5.5% in 2016 (risk ratio, 4.66, 95% confidence interval, 2.38-9.11) while use of fertility-preserving procedures increased from 1.0% to 4.6% (risk ratio, 3.84, 95% confidence interval, 1.94-7.59) during the same time period. In a multivariable model, use of any fertility-preserving interventions were more common in patients with breast cancer (adjusted risk ratio, 2.30, 95% confidence interval, 1.30-4.06), those in the Northeast (adjusted risk ratio, 1.24, 95% confidence interval, 1.10-1.40), and in younger women (18-35 years) (adjusted risk ratio, 2.59, 95% confidence interval, 2.32-2.89). CONCLUSION: Although limited by lack of information regarding cancer stage and desire for future fertility, only a small fraction of reproductive-aged female cancer patients receiving chemotherapy are evaluated in a nationwide sample for fertility preservation or undergo fertility-preserving procedures.
引用
- Selter J, Huang Y, Grossman Becht LC, et al. Use of fertility preservation services in female reproductive-aged cancer patients. Am J Obstet Gynecol. 2019. PMID: 31108063. doi:10.1016/j.ajog.2019.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。